Clinical trial

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

NCT03425838

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention CDK 4/6 inhibitor Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Non-Steroidal Aromatase Inhibitor Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrantView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2017-11-09

PhasePHASE3

Conditions

Breast Neoplasm Femaleunresolved

Interventions

CDK 4/6 inhibitorDRUG

Non-Steroidal Aromatase InhibitorDRUG

FulvestrantDRUG · verified · RxNorm: fulvestrant

Sponsors & collaborators

Borstkanker Onderzoek Groeplead sponsor

Mapped research locations

AmsterdamNetherlands5 RotterdamNetherlands4 GroningenNetherlands2 NijmegenNetherlands2 UtrechtNetherlands2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03425838 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.